GO:0016274 protein-arginine N-methyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016274 (protein-arginine N-methyltransferase activity, PRMT activity) catalyzes the transfer of a methyl group from S-adenosyl-L-methionine to the guanidino nitrogen of a protein arginine residue, producing S-adenosyl-L-homocysteine and a methyl-arginine.
• PRMT family enzymes regulate histone and non-histone proteins, controlling transcription, RNA processing, signal transduction and autophagy.
• Dysregulated PRMT activity drives oncogenesis, metabolic reprogramming, immune dysfunction and muscle wasting, making these enzymes attractive drug targets.
• PRMT1, PRMT2, PRMT4/CARM1 and PRMT9 are among the best-characterized members, with distinct substrate specificities and disease links.
• Small-molecule PRMT inhibitors are in active preclinical and patent development, underscoring the therapeutic relevance of this activity.
• CRISPR knockout, point-mutation, knock-in and overexpression models are essential to dissect which PRMT functions are catalytic versus scaffolding in disease.
Description
Protein-arginine N-methyltransferase activity (GO:0016274), also known as PRMT activity, is a fundamental enzymatic function that post-translationally modifies proteins by adding methyl groups to arginine residues. This activity uses S-adenosyl-L-methionine (SAM) as the methyl donor and releases S-adenosyl-L-homocysteine (SAH), thereby linking cellular methylation capacity to protein function. Because arginine methylation alters protein-protein interactions, stability and catalytic activity, PRMTs sit at the crossroads of transcription, RNA biology and signal transduction. Researchers study GO:0016274 to understand how cells interpret metabolic and environmental cues, and how disruption of this activity contributes to cancer, immune disorders and tissue degeneration. The clinical importance of PRMTs is highlighted by ongoing efforts to develop selective inhibitors for oncology and inflammatory diseases.
protein-arginine N-methyltransferase activity At A Glance
| GO ID | GO:0016274 |
|---|---|
| GO term | protein-arginine N-methyltransferase activity |
| Ontology | molecular_function |
| Synonym | PRMT activity |
| Definition | Catalysis of the reaction: S-adenosyl-L-methionine + (protein)-arginine = S-adenosyl-L-homocysteine + (protein)-N-methyl-arginine. |
| Major function | Post-translational methylation of protein arginine residues, regulating protein interactions, localization and activity. |
| Cofactor | S-adenosyl-L-methionine (SAM) as methyl donor; S-adenosyl-L-homocysteine (SAH) as product. |
| Representative enzymes | PRMT1, PRMT2, PRMT4/CARM1, PRMT9 and other PRMT family members. |
| Disease relevance | Cancer, sepsis-associated lymphopenia, skeletal muscle atrophy and immune dysregulation. |
What Is GO:0016274?
GO:0016274 describes the catalytic activity of enzymes that transfer a methyl group from S-adenosyl-L-methionine to the nitrogen atoms of a protein arginine residue, forming a methyl-arginine and S-adenosyl-L-homocysteine. This activity is synonymous with PRMT activity and is carried out by a family of enzymes that share a conserved methyltransferase domain but differ in substrate specificity and product type.
Why Is protein-arginine N-methyltransferase activity Important in Cell Biology?
Protein-arginine N-methyltransferase activity is important because it directly controls the methylation status of key regulatory proteins, including histones and signaling molecules, thereby influencing gene expression, cell growth and immune responses. Aberrant PRMT activity has been linked to oncogenesis, metabolic disorders and tissue wasting, and pharmacological inhibition of these enzymes is being actively pursued as a therapeutic strategy.
• Regulates histone methylation and chromatin-dependent transcription.
• Controls non-histone protein functions in RNA processing and signal transduction.
• Drives oncogenic transformation and tumor growth in hepatocellular carcinoma and other cancers.
• Modulates immune responses and contributes to sepsis-induced lymphopenia.
• Participates in skeletal muscle atrophy and autophagy regulation.
• Provides a druggable target for small-molecule inhibitors in oncology and inflammation.
• Links cellular metabolism (SAM/SAH ratio) to protein function.
• Serves as a model for studying post-translational modification crosstalk.
• Enables CRISPR-based functional dissection of catalytic versus non-catalytic roles.
• Offers biomarkers and therapeutic hypotheses for metabolic and degenerative diseases.
What Happens During protein-arginine N-methyltransferase activity?
Substrate recognition and binding
In simple terms: The enzyme first grabs the target protein and the methyl donor.
PRMT enzymes recognize specific arginine-containing motifs in substrate proteins and bind the cofactor S-adenosyl-L-methionine (SAM) in their catalytic pocket. Substrate specificity is determined by sequences flanking the target arginine and by accessory domains or interacting proteins.
Methyl group transfer
In simple terms: The enzyme moves a methyl group from SAM onto the arginine.
The catalytic domain of the PRMT transfers the methyl group from SAM to the guanidino nitrogen of the substrate arginine, generating S-adenosyl-L-homocysteine (SAH) and a methyl-arginine residue. Depending on the enzyme, the product can be monomethylarginine or asymmetric/symmetric dimethylarginine.
Product release and substrate fate
In simple terms: After methylation, the modified protein goes on to do its job differently.
Release of the methylated protein and SAH allows the modified substrate to engage downstream effectors, altering protein-protein interactions, localization or activity. For example, PRMT9-mediated methylation of MAVS attenuates its activation in antiviral signaling.
Crosstalk with other modifications
In simple terms: Methylation can compete or cooperate with other protein marks.
Arginine methylation can influence or be influenced by other post-translational modifications, such as phosphorylation and ubiquitination, thereby shaping signaling outcomes. FBXO7-mediated ubiquitination of PRMT1, for instance, suppresses serine synthesis and tumor growth, illustrating crosstalk between methylation and ubiquitination.
Key Genes Involved in GO:0016274 protein-arginine N-methyltransferase activity
The following genes encode enzymes or regulators directly associated with protein-arginine N-methyltransferase activity (GO:0016274) and have been experimentally linked to its functions.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PRMT1 | Major asymmetric arginine methyltransferase; methylates histones and non-histone proteins | Oncogenesis, serine synthesis, tumor growth |
| PRMT2 | Noncatalytic regulator of PRMT1-mediated histone methylation | Modulates PRMT1 activity and chromatin states |
| PRMT4 (CARM1) | Arginine methyltransferase involved in transcription and autophagy | Sepsis-induced lymphopenia, skeletal muscle atrophy |
| PRMT9 | Arginine methyltransferase that methylates MAVS | Antiviral signaling and immune regulation |
| FBXO7 | E3 ubiquitin ligase that ubiquitinates PRMT1 | Suppresses serine synthesis and hepatocellular carcinoma growth |
| MAVS | Mitochondrial antiviral signaling protein; substrate of PRMT9 | Innate immune signaling |
| SAM (cofactor) | Methyl donor for all PRMT reactions | Links metabolism to methylation |
| SAH (product) | Byproduct of methyl transfer; feedback inhibitor | Reflects methylation flux |
| Histone H3 | Substrate of PRMT1/PRMT4 at arginine residues | Chromatin regulation and transcription |
| Histone H4 | Substrate of PRMT1/PRMT4 at arginine residues | Chromatin regulation and transcription |
| PRMT family (general) | Enzymes catalyzing GO:0016274 | Drug discovery and inhibitor development |
| CARM1 (PRMT4) | Autophagy and mitophagy regulator | Fasting-induced skeletal muscle atrophy |
| PRMT4 (CARM1) | Glucose-induced muscle atrophy mediator | Metabolic stress in skeletal muscle |
| PRMT1 (ubiquitination) | Regulated by FBXO7 | Hepatocellular carcinoma |
| PRMT9 (MAVS) | Attenuates MAVS activation | Antiviral immunity |
| PRMT2 (noncatalytic) | Scaffold for PRMT1 | Histone methylation activity |
| PRMT inhibitors (chemical) | Small molecules targeting PRMT activity | Therapeutic development |
| SAM/SAH ratio | Metabolic indicator of methylation potential | Muscle atrophy and metabolic disease |
How Is protein-arginine N-methyltransferase activity Regulated?
Protein-arginine N-methyltransferase activity is regulated at multiple levels. The availability of the methyl donor SAM and the accumulation of the product SAH provide metabolic feedback that can influence enzyme activity. Protein-protein interactions, such as the noncatalytic role of PRMT2 in modulating PRMT1-mediated histone methylation, add another layer of control. Post-translational modifications of PRMTs themselves, including ubiquitination by FBXO7, can alter their stability and function. In pathophysiological contexts, glucose-induced signaling and fasting-related pathways regulate PRMT4/CARM1 activity in skeletal muscle, and immune stimuli can affect PRMT9-mediated MAVS methylation.
protein-arginine N-methyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PRMT1 | Hepatocellular carcinoma, oncogenesis | Knockout or point-mutation in liver cancer cell lines |
| PRMT4 (CARM1) | Sepsis-induced lymphopenia, skeletal muscle atrophy | Knockout mice or muscle cell lines under glucose/fasting stress |
| PRMT9 | Antiviral immunity (MAVS signaling) | Knockout or knock-in in immune cells |
| PRMT2 | Chromatin regulation (noncatalytic role) | Knockout or overexpression in cancer cells |
| FBXO7 | Hepatocellular carcinoma (PRMT1 regulation) | Overexpression or knockout in liver cancer models |
Cancer
PRMT activity is frequently dysregulated in cancer. PRMT1-dependent oncogenesis has been demonstrated in leukemia models, where PRMT1-mediated methylation drives transformation. In hepatocellular carcinoma, FBXO7 ubiquitinates PRMT1 to suppress serine synthesis and tumor growth, indicating that PRMT1 activity supports tumor metabolism. These findings position PRMT enzymes as potential therapeutic targets, and small-molecule PRMT inhibitors are under active development.
Immune dysfunction and sepsis
PRMT4 (CARM1) contributes to lymphopenia in experimental sepsis, linking arginine methylation to immune cell survival and inflammation. PRMT9 attenuates MAVS activation through arginine methylation, thereby tuning antiviral innate immune responses. Together, these studies show that PRMT activity is critical for balanced immune signaling.
Skeletal muscle atrophy and metabolic stress
PRMT4 activation contributes to glucose-induced skeletal muscle atrophy, and CARM1 drives mitophagy and autophagy flux during fasting-induced skeletal muscle atrophy. These findings connect PRMT activity to metabolic stress responses and muscle wasting, suggesting that PRMT inhibitors might have therapeutic potential in muscle degenerative conditions.
From protein-arginine N-methyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is PRMT1 catalytic activity required for tumor growth? | PRMT1 knockout or catalytically dead point-mutant knock-in in cancer cell lines |
| Does PRMT4 drive muscle atrophy? | PRMT4 knockout or overexpression in skeletal muscle cells or mice |
| How does PRMT9 methylation affect MAVS signaling? | PRMT9 knockout or point-mutation in immune cells |
| What is the noncatalytic role of PRMT2 in histone methylation? | PRMT2 knockout and rescue with wild-type or mutant PRMT2 |
| Can PRMT inhibitors phenocopy genetic loss? | Overexpression models treated with small-molecule PRMT inhibitors |
| Does FBXO7 regulate PRMT1 stability? | FBXO7 knockout or overexpression with PRMT1 tagged knock-in |
How to Study the protein-arginine N-methyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro methyltransferase assay | Catalytic transfer of methyl groups to substrates | Enzyme kinetics and inhibitor screening |
| Mass spectrometry | Methylarginine sites and stoichiometry | Mapping PRMT substrates in cells |
| CRISPR knockout | Loss-of-function phenotypes | Determining requirement for PRMT genes |
| CRISPR point mutation | Catalytic versus noncatalytic functions | Dissecting enzymatic activity in disease |
| RNA-seq | Transcriptional changes | Downstream effects of PRMT perturbation |
| Proteomics | Protein abundance and modifications | Identifying PRMT-regulated pathways |
| Autophagy flux assays | Autophagic degradation | Studying CARM1 in muscle atrophy |
| Immune cell functional assays | Lymphopenia and cytokine signaling | Evaluating PRMT4/PRMT9 in immunity |
Biochemical assays for PRMT activity
In vitro methyltransferase assays using recombinant PRMT enzymes and substrate peptides or proteins in the presence of radiolabeled or fluorescent SAM can directly measure catalytic activity. These assays are essential for determining kinetic parameters and testing inhibitors.
Mass spectrometry-based methylarginine profiling
Mass spectrometry can identify and quantify methylarginine residues on substrate proteins, providing site-specific information about PRMT activity in cells and tissues. This approach is powerful for mapping global changes in arginine methylation upon genetic or pharmacological perturbation.
CRISPR-based functional genomics
CRISPR knockout, point-mutation and knock-in models allow researchers to dissect the catalytic versus noncatalytic functions of PRMTs in disease contexts. For example, catalytically dead PRMT1 knock-in can separate methylation-dependent from scaffolding roles.
Transcriptomics and proteomics
RNA-seq and proteomics can reveal downstream consequences of altered PRMT activity, such as changes in gene expression, serine synthesis pathways or immune signaling. These methods help link GO:0016274 to broader cellular phenotypes.
How CRISPR Can Be Used to Study GO:0016274 protein-arginine N-methyltransferase activity
Knockout
CRISPR knockout of PRMT genes such as PRMT1, PRMT4 or PRMT9 eliminates enzyme expression, enabling researchers to test whether the activity is required for specific phenotypes like tumor growth, immune signaling or muscle atrophy. Knockout models are often the first step in validating a gene's causal role.
Point Mutation
Introducing catalytically dead point mutations into PRMT genes (e.g., in the catalytic domain) allows separation of methylation-dependent functions from scaffolding or noncatalytic roles. This is particularly important for PRMT2, which plays a noncatalytic role in PRMT1-mediated histone methylation.
Knock-in
Knock-in of tagged or mutant PRMT alleles (e.g., FLAG-tagged PRMT1 or disease-associated variants) facilitates biochemical purification, imaging and analysis of protein interactions in a physiological context. Knock-in models can also be used to express PRMT substrates with modified methylation sites.
Overexpression
CRISPR activation or cDNA overexpression of PRMTs can model gain-of-function states observed in cancer and metabolic disease, helping to establish whether increased PRMT activity is sufficient to drive pathological phenotypes. Overexpression models are also useful for testing PRMT inhibitors.
How EDITGENE Supports protein-arginine N-methyltransferase activity Research
Researchers studying protein-arginine N-methyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in a disease phenotype or merely correlated with it. This requires precise genetic models that can isolate catalytic activity, protein interactions and expression levels. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate such functional studies.
Contact EDITGENE today to design your custom CRISPR model for protein-arginine N-methyltransferase activity research.
Frequently Asked Questions About protein-arginine N-methyltransferase activity
What is protein-arginine N-methyltransferase activity?
It is the enzymatic activity (GO:0016274) that transfers a methyl group from S-adenosyl-L-methionine to a protein arginine residue, producing a methyl-arginine and S-adenosyl-L-homocysteine.
What genes are involved in protein-arginine N-methyltransferase activity?
Key genes include PRMT1, PRMT2, PRMT4/CARM1 and PRMT9, which encode enzymes with this activity, as well as regulators like FBXO7.
What diseases are linked to PRMT activity?
PRMT activity has been linked to cancer, sepsis-induced lymphopenia, skeletal muscle atrophy and immune dysregulation.
How is protein-arginine N-methyltransferase activity regulated?
It is regulated by SAM/SAH availability, protein-protein interactions (e.g., PRMT2 with PRMT1), ubiquitination (e.g., FBXO7 on PRMT1) and metabolic signals.
What is the role of PRMT1 in cancer?
PRMT1-mediated arginine methylation drives oncogenesis and supports tumor metabolism; its ubiquitination by FBXO7 suppresses serine synthesis and tumor growth.
How does PRMT4 contribute to muscle atrophy?
PRMT4 activation contributes to glucose-induced skeletal muscle atrophy and drives mitophagy and autophagy flux during fasting-induced atrophy.
What is the function of PRMT9 in immunity?
PRMT9 attenuates MAVS activation through arginine methylation, thereby tuning antiviral innate immune signaling.
Can PRMT activity be inhibited therapeutically?
Yes, small-molecule PRMT inhibitors are under active development and have been reviewed in patent literature for cancer and other diseases.
What research methods are used to study PRMT activity?
Common methods include in vitro methyltransferase assays, mass spectrometry, CRISPR knockout/point-mutation models, RNA-seq and proteomics.
Why use CRISPR models for PRMT research?
CRISPR knockout, point-mutation, knock-in and overexpression models allow precise dissection of catalytic versus noncatalytic functions and validation of causal roles in disease.
Conclusion
Protein-arginine N-methyltransferase activity (GO:0016274) is a central post-translational modification that impacts transcription, signaling, immunity and metabolism. Its dysregulation contributes to cancer, immune disorders and muscle wasting, and its enzymatic components are promising drug targets. Continued research using advanced CRISPR models and multi-omics approaches will clarify how PRMTs can be therapeutically modulated.
References
- 1. Kumar P et al.. 2025. Protein Arginine N-Methyltransferase 4 Activation Contributes to Glucose-Induced Skeletal Muscle Atrophy.. FASEB J 39(20):e71135 PMID: 41078314
- 2. Rowley MJ et al.. 2023. Protein arginine N-methyltransferase 2 plays a noncatalytic role in the histone methylation activity of PRMT1.. J Biol Chem 299(12):105360 PMID: 37863263
- 3. Luo L et al.. 2024. FBXO7 ubiquitinates PRMT1 to suppress serine synthesis and tumor growth in hepatocellular carcinoma.. Nat Commun 15(1):4790 PMID: 38839752
- 4. Lai Y et al.. 2023. Protein arginine N-methyltransferase 4 (PRMT4) contributes to lymphopenia in experimental sepsis.. Thorax 78(4):383-393 PMID: 35354645
- 5. Bai X et al.. 2022. The protein arginine methyltransferase PRMT9 attenuates MAVS activation through arginine methylation.. Nat Commun 13(1):5016 PMID: 36028484
- 6. Dong J et al.. 2022. An updated patent review of protein arginine N-methyltransferase inhibitors (2019-2022).. Expert Opin Ther Pat 32(12):1185-1205 PMID: 36594709
- 7. Stouth DW et al.. 2024. CARM1 drives mitophagy and autophagy flux during fasting-induced skeletal muscle atrophy.. Autophagy 20(6):1247-1269 PMID: 38018843
- 8. Cheung N et al.. 2007. Protein arginine-methyltransferase-dependent oncogenesis.. Nat Cell Biol 9(10):1208-15 PMID: 17891136
